Stock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales

Stock Track

02-27

Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.

The key highlights from Immunocore's earnings report include:

KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.
Progress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.
Advancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.
Initiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.
Cash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.

Immunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1191083799"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191083799\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1191083799?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191083799","market":"us","top_or_hot":-1,"title":"Stock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales","media":"Stock Track","content":"<p>Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.</p>\n\n<p>The key highlights from Immunocore's earnings report include:</p>\n\n<ul>\n<li>KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.</li>\n<li>Progress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.</li>\n<li>Advancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.</li>\n<li>Initiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.</li>\n<li>Cash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.</li>\n</ul>\n\n<p>Immunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immunocore Holdings Soars 5.17% as Earnings Beat Expectations on Strong KIMMTRAK Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 00:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.</p>\n\n<p>The key highlights from Immunocore's earnings report include:</p>\n\n<ul>\n<li>KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.</li>\n<li>Progress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.</li>\n<li>Advancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.</li>\n<li>Initiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.</li>\n<li>Cash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.</li>\n</ul>\n\n<p>Immunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMCR","symbol_name":"Immunocore Holdings plc","start_time":0,"source_url":"","article_id":"1191083799","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191083799","pubTimestamp":1740587685,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Immunocore Holdings plc , a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.The key highlights from Immunocore's earnings report include:. KIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMCR":"Immunocore Holdings plc"},"translate_title":"股票轨迹Immunocore Holdings飙升5.17%，KIMMTRAK销售强劲，盈利超出预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMCR":1},"content_text":"Immunocore Holdings plc (IMCR), a commercial-stage biotechnology company, saw its stock soar 5.17% in intraday trading on Wednesday, February 26, 2025. The surge followed the company's impressive fourth quarter and full-year 2024 financial results, driven by strong sales of its lead product, KIMMTRAK.\nThe key highlights from Immunocore's earnings report include:\n\nKIMMTRAK net sales of $84.1 million for Q4 2024 and $310.0 million for the full year, marking 11 consecutive quarters of revenue growth since its launch.\nProgress in expanding KIMMTRAK's indications, with enrollment ongoing in two Phase 3 trials (TEBE-AM and ATOM) for additional melanoma indications.\nAdvancement of the PRAME portfolio, with the first patient randomized in the Phase 3 PRISM-MEL-301 trial for brenetafusp in first-line advanced cutaneous melanoma.\nInitiation of Phase 1 trials for IMC-P115C (PRAME-A02) and IMC-R117C (PIWIL1), targeting additional cancer types.\nCash, cash equivalents, and marketable securities of $820.4 million as of December 31, 2024, providing a strong financial position.\n\nImmunocore's CEO, Bahija Jallal, expressed confidence in the company's growth prospects, citing the continued execution of KIMMTRAK's lifecycle management program, advancement of the clinical pipeline, and expansion into autoimmune diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}